OncoMatch/Clinical Trials/NCT03970447
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Is NCT03970447 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2/3 trial studies multiple treatments for glioblastoma.
Treatment: Temozolomide · Lomustine · Regorafenib · Paxalisib · VAL-083 · VT1021 · Troriluzole · ADI-PEG 20 · AZD1390 · Tinostamustine — Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. All institutions are enrolling Newly Diagnosed participants. Institutions also enrolling Recurrent participants are marked with an asterisk (\*).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 wild-type
Required: IDH2 wild-type
Disease stage
Required: Stage GRADE IV
Grade: iv (who)
Prior therapy
Must have received: radiation therapy — recurrent gbm
Cannot have received: prolifeprospan 20 with carmustine wafer (prolifeprospan 20 with carmustine wafer)
Cannot have received: intracerebral, intratumoral, or cerebral spinal fluid (csf) agent
Cannot have received: radiation therapy for gbm or lower-grade glioma
Cannot have received: chemotherapy or immunotherapy for gbm or lower-grade glioma
Cannot have received: lomustine (lomustine)
Cannot have received: agents part of any of the experimental arms
Cannot have received: bevacizumab or other vascular endothelial growth factor (vegf) or vegf receptor-mediated targeted agent (bevacizumab)
Cannot have received: prolifeprospan 20 with carmustine wafer (prolifeprospan 20 with carmustine wafer)
Cannot have received: intracerebral agent
Lab requirements
Cardiac function
qtc > 470 msec excluded
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- University of California, San Diego · La Jolla, California
- Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute · Los Angeles, California
- University of California, Los Angeles · Los Angeles, California
- St. Joseph Hospital · Orange, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03970447 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior prolifeprospan 20 with carmustine wafer, intracerebral, intratumoral, or cerebral spinal fluid (csf) agent, radiation therapy for gbm or lower-grade glioma disqualifies patients from enrollment.
Does this trial require IDH1?
Yes, IDH1 wild-type is a required biomarker for enrollment.
Does this trial require IDH2?
Yes, IDH2 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage GRADE IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages